Ian F Tannock

Summary

Publications

  1. pmc The tumor microenvironment and strategies to improve drug distribution
    Jasdeep K Saggar
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Front Oncol 3:154. 2013
  2. doi request reprint Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Ian F Tannock
    Princess Margaret Cancer Centre, Toronto, Canada
    Lancet Oncol 14:760-8. 2013
  3. doi request reprint Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts
    Andrea S Fung
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    Clin Cancer Res 15:5389-95. 2009
  4. ncbi request reprint Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study
    Helen G Mar Fan
    Princess Margaret Hospital and University of Toronto, Ontario, Canada
    J Clin Oncol 23:8025-32. 2005
  5. ncbi request reprint Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
    Jasdeep K Saggar
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Int J Cancer 134:2726-34. 2014
  6. doi request reprint Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital Ambulatory Care, Princess Margaret Hospital Toronto General Research Institute, University of Toronto and University Health Network Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Toronto Department of Medical Oncology, R S McLaughlin Durham Regional Cancer Centre, Oshawa Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Am J Clin Oncol 36:436-42. 2013
  7. doi request reprint A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Toronto, ON, Canada
    Invest New Drugs 31:1008-15. 2013
  8. doi request reprint Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor
    Andrea S Fung
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Cancer Chemother Pharmacol 72:585-95. 2013
  9. doi request reprint A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5 222, Toronto, Ontario M5G 2M9, Canada
    Invest New Drugs 29:1045-9. 2011
  10. doi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008

Detail Information

Publications71

  1. pmc The tumor microenvironment and strategies to improve drug distribution
    Jasdeep K Saggar
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Front Oncol 3:154. 2013
    ..In this review, we describe important features of the tumor microenvironment and discuss strategies whereby drug distribution and activity may be improved...
  2. doi request reprint Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Ian F Tannock
    Princess Margaret Cancer Centre, Toronto, Canada
    Lancet Oncol 14:760-8. 2013
    ..We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone...
  3. doi request reprint Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts
    Andrea S Fung
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    Clin Cancer Res 15:5389-95. 2009
    ..We compared the effects of concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus (CCI-779) on tumor cells and xenografts...
  4. ncbi request reprint Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study
    Helen G Mar Fan
    Princess Margaret Hospital and University of Toronto, Ontario, Canada
    J Clin Oncol 23:8025-32. 2005
    ..We previously evaluated fatigue, menopausal symptoms, and cognitive dysfunction in patients receiving adjuvant therapy for breast cancer and matched healthy women. Here we report assessment of these women 1 and 2 years later...
  5. ncbi request reprint Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
    Jasdeep K Saggar
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Int J Cancer 134:2726-34. 2014
    ..When given with doxorubicin or docetaxel, TH-302 complements and enhances anticancer effects in both perivascular and hypoxic regions but also increases toxicity...
  6. doi request reprint Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital Ambulatory Care, Princess Margaret Hospital Toronto General Research Institute, University of Toronto and University Health Network Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Toronto Department of Medical Oncology, R S McLaughlin Durham Regional Cancer Centre, Oshawa Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Am J Clin Oncol 36:436-42. 2013
    ..This study assessed the feasibility of conducting a randomized trial of less frequent bisphosphonate administration in women with breast cancer and low-risk bone metastases...
  7. doi request reprint A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Toronto, ON, Canada
    Invest New Drugs 31:1008-15. 2013
    ..In this single arm phase 2 study, we evaluated the efficacy and tolerability of cediranib (AZD2171) a potent angiogenesis inhibitor in first line mRCC...
  8. doi request reprint Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor
    Andrea S Fung
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Cancer Chemother Pharmacol 72:585-95. 2013
    ..Here, we evaluate the hypothesis that sequential administration might allow inhibition of repopulation by gefitinib, with tumor cells re-entering cycle to allow sensitivity to subsequent chemotherapy...
  9. doi request reprint A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5 222, Toronto, Ontario M5G 2M9, Canada
    Invest New Drugs 29:1045-9. 2011
    ..Secondary endpoints included rate of prolonged stable disease (>3 months), time to progression, median and 1 yr survival and safety and tolerability...
  10. doi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008
    ..Here, we report an updated analysis of survival...
  11. doi request reprint Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues
    Krupa J Patel
    Department of Medical Biophysics, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
    Cancer Chemother Pharmacol 72:127-38. 2013
    ..Here, we compare the time-dependent spatial distribution of three anticancer drugs within tumors, heart, kidney, liver and brain...
  12. ncbi request reprint Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
    Arnoud J Templeton
    Affiliations of authors Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada AJT, MGM, FEV B, PA, RL A, JJK, IFT, EA Department of Medical Oncology, Institute of Oncology Ljubljana, Slovenia BS Medical Oncology University Hospital, Albacete, Spain AO University of Alabama, Birmingham Comprehensive Cancer Center, Birmingham, AL GS Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia BT
    J Natl Cancer Inst 106:dju124. 2014
    ..Here we quantify the prognostic impact of this biomarker and assess its consistency in solid tumors...
  13. doi request reprint Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors
    Jasdeep K Saggar
    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Mol Cancer Ther 12:542-52. 2013
    ..The above biomarkers may be used in designing strategies to overcome therapeutic resistance by modifying or complementing the limited spatial distribution of drug activity in solid tumors...
  14. doi request reprint Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
    Francisco E Vera-Badillo
    Affiliations of authors Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada FEV B, AJT, PDG, ID P, PLB, MA M, IFT, AO, EA Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia BS Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain AO
    J Natl Cancer Inst 106:djt319. 2014
    ..Preclinical data suggest that expression of AR may modify clinical outcomes in early breast cancer with improved prognosis in estrogen receptor (ER)-positive disease and poorer prognosis in ER-negative disease...
  15. doi request reprint Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials
    Arif Manji
    Arif Manji, Irene Brana, Eitan Amir, Ian F Tannock, Philippe L Bedard, Amit Oza, Lillian L Siu, and Albiruni R Abdul Razak, Princess Margaret Cancer Centre, University Health Network George Tomlinson, University of Toronto and Arif Manji, Hospital for Sick Children, Toronto, and Southlake Regional Health Centre, Newmarket, Ontario, Canada
    J Clin Oncol 31:4260-7. 2013
    ..To evaluate the use and objectives of expansion cohorts in phase I cancer trials and to explore trial characteristics associated with their use...
  16. pmc The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
    Krupa J Patel
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    BMC Cancer 9:356. 2009
    ..Here we evaluate the effect of PgP expression on doxorubicin distribution in vivo...
  17. doi request reprint Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 29:2543-9. 2011
    ..The relationship between market pricing of new anticancer drugs and the magnitude of clinical benefit caused by them has not been reported...
  18. doi request reprint The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs
    Saroj Niraula
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 30:3012-9. 2012
    ..There is relatively less emphasis on toxicity. In our study, we analyze serious toxicities of newly approved anticancer drugs reported in pivotal RCTs used for drug registration...
  19. ncbi request reprint Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
    Francisco E Vera-Badillo
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Breast Cancer Res Treat 146:235-44. 2014
    ..Further validation of the independent prognostic impact of multifocality is warranted. ..
  20. doi request reprint When are "positive" clinical trials in oncology truly positive?
    Alberto Ocana
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    J Natl Cancer Inst 103:16-20. 2011
    ....
  21. ncbi request reprint Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy
    Licun Wu
    Division of Experimental Therapeutics, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Clin Cancer Res 11:8195-200. 2005
    ..The scheduling of short-acting hormonal agents between courses of adjuvant chemotherapy for human breast cancer has potential to improve the outcome of treatment...
  22. pmc The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
    Carol M Lee
    Divisions of Applied Molecular Oncology and Medical Oncology and Hematology Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    BMC Cancer 10:255. 2010
    ..Poor distribution of some anticancer drugs in solid tumors may limit their anti-tumor activity...
  23. ncbi request reprint Assessing cognitive function in cancer patients
    Janette Vardy
    Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Support Care Cancer 14:1111-8. 2006
    ..Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments...
  24. ncbi request reprint A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer
    Helen G Mar Fan
    Princess Margaret Hospital and University of Toronto, 610 University Ave, Suite 5 218, Toronto, Ontario, M5G 2M9, Canada
    Support Care Cancer 16:577-83. 2008
    ..Women who receive adjuvant chemotherapy for breast cancer develop fatigue, and a subset reports cognitive impairment. Methylphenidate is reported to improve fatigue and to decrease cognitive impairment in other populations...
  25. doi request reprint The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone
    Olivier Tredan
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 69:940-7. 2009
    ..This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone...
  26. doi request reprint Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Eitan Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Eur J Cancer 48:385-8. 2012
    ..Composite measures comprising patient reported outcomes and intermediate endpoints such as PFS may be the solution and should be investigated further...
  27. doi request reprint Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
    Man Yu
    Ontario Cancer Institute Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Cancer Metastasis Rev 32:211-27. 2013
    ..We also outline new MDR-reversing strategies that directly target ABC transporters or circumvent relevant signaling pathways...
  28. doi request reprint Phase II trial of mirtazapine for cancer-related cachexia and anorexia
    Rachel P Riechelmann
    Department of Medical Oncology, University of Toronto, Canada
    Am J Hosp Palliat Care 27:106-10. 2010
    ..2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA...
  29. pmc Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib
    Rama H Grantab
    Division of Research, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    BMC Cancer 12:214. 2012
    ..Limited penetration of anticancer drugs in solid tumours is a probable cause of drug resistance. Our previous results indicate that drug penetration depends on cellular packing density and adhesion between cancer cells...
  30. ncbi request reprint Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research
    Janette Vardy
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2455-63. 2007
    ..There is evidence that some cancer survivors suffer cognitive impairment after chemotherapy. Determining if a patient has cognitive impairment is challenging, especially because impairment is usually subtle...
  31. doi request reprint Sorafenib for metastatic renal cancer: the Princess Margaret experience
    Rachel P Riechelmann
    Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Am J Clin Oncol 31:182-7. 2008
    ..Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program...
  32. ncbi request reprint Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
    Nadine Tchen
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:4175-83. 2003
    ..Here, we determine their incidence and severity, and interrelationships between them and quality of life...
  33. doi request reprint Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers
    Neesha C Dhani
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    BJU Int 110:840-5. 2012
    ..The presence of serum TMPRSS2-ERG and SPINK1 mRNA biomarkers recovered from blood suggest that their analysis is worthy of further study...
  34. pmc Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel
    Andrea S Fung
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Neoplasia 14:324-34. 2012
    ....
  35. doi request reprint Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials
    Bostjan Seruga
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:174-85. 2011
    ..Here, we analyze adverse drug reactions (ADRs) of targeted anticancer agents from updated drug labels and their reporting in corresponding pivotal RCTs...
  36. pmc Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
    Saroj Niraula
    Division of Medical Oncology, Princess Margaret Hospital University of Toronto, Toronto, ON
    Can Urol Assoc J 7:E74-81. 2013
    ....
  37. doi request reprint Drug resistance in metastatic castration-resistant prostate cancer
    Bostjan Seruga
    Princess Margaret Hospital, University of Toronto, ON, Canada
    Nat Rev Clin Oncol 8:12-23. 2011
    ..New therapeutics targeting these mechanisms are under evaluation in clinical trials. Drug resistance in metastatic CRPC is multifactorial and complex and development of new medical therapies remains challenging...
  38. ncbi request reprint Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment
    Fiona P Downie
    Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Psychooncology 15:921-30. 2006
    ..Here we compare assessment of these symptoms using self-report questionnaires and a researcher-administered screen of cognitive function with the experience of women as revealed in a semi-structured interview...
  39. ncbi request reprint Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Licun Wu
    Department of Medical Oncology and Hematology and Division of Experimental Therapeutics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 65:2825-31. 2005
    ..Our results suggest that repopulation of PTEN-negative cancer cells between courses of chemotherapy might be inhibited by CCI-779...
  40. ncbi request reprint Long-term outcome of radiation-based conservation therapy for invasive bladder cancer
    Peter W M Chung
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network and University of Toronto, Toronto, Ontario M5G 2M9, Canada
    Urol Oncol 25:303-9. 2007
    ..To report the long-term results and examine factors associated with bladder preservation, risk of relapse, and survival in patients treated with radical radiotherapy for invasive bladder cancer...
  41. ncbi request reprint A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
    Monika K Krzyzanowska
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    Cancer Chemother Pharmacol 60:135-41. 2007
    ..The lack of effective systemic therapies for patients with advanced renal cell carcinoma (RCC) has stimulated interest in evaluating novel treatment strategies for this disease...
  42. ncbi request reprint Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Cancer 95:2516-23. 2002
    ..Results from Phase II trials conducted in Asia have shown that gemcitabine alone (GEM) or with cisplatin (GC) is active among patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC)...
  43. ncbi request reprint Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status
    Mala Bahl
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 60:1127-36. 2004
    ..The Intergroup 0099 trial (INT 0099) for locally advanced nasopharyngeal cancer (NPC) has set a standard of practice. This retrospective review documents our institutional experience with this regimen...
  44. ncbi request reprint Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy
    Wu Licun
    Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario M5G 2M9 Canada
    Clin Cancer Res 9:4614-8. 2003
    ..Here we study inhibition of repopulation of hormone-responsive human breast cancer cell lines by selective estrogen receptor (ER) modulators (SERMs) during courses of chemotherapy...
  45. ncbi request reprint The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
    Helen G Juffs
    Princess Margaret Hospital, Ontario, Toronto, Canada
    Lancet Oncol 3:738-47. 2002
    ..Other trials should address the role of molecular markers in selecting patients for chemotherapy. Whenever possible, chemotherapy for locally advanced muscle-invasive TCC should be given in the context of a well-designed clinical trial...
  46. ncbi request reprint Potential drug interactions and duplicate prescriptions among cancer patients
    Rachel P Riechelmann
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Natl Cancer Inst 99:592-600. 2007
    ..Cancer patients receive numerous medications, including antineoplastic agents, drugs for supportive care, and medications for comorbid illnesses. Therefore, they are at risk for drug interactions and duplicate prescribing...
  47. doi request reprint Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia
    Robert M Staruch
    Centre for Research in Image Guided Therapeutics, Sunnybrook Research Institute, Toronto, Ontario, Canada
    Int J Hyperthermia 28:776-87. 2012
    ....
  48. ncbi request reprint Drug penetration in solid tumours
    Andrew I Minchinton
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
    Nat Rev Cancer 6:583-92. 2006
    ....
  49. doi request reprint Phase III trials of targeted anticancer therapies: redesigning the concept
    Alberto Ocana
    Authors Affiliation Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada
    Clin Cancer Res 19:4931-40. 2013
    ..Here, we review these problems and suggest that phase III trials with adaptive designs in selected prescreened populations could reduce these limitations...
  50. doi request reprint Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center
    Grace Lun
    School of Medicine, Queen s University, Toronto, Ontario, Canada
    Clin Genitourin Cancer 11:342-345.e1. 2013
    ..In this study we examined the use of a study screener to enhance accrual and highlight bone health issues in a tertiary referral cancer center...
  51. ncbi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    ..We compared such treatment with docetaxel plus prednisone in men with this disease...
  52. doi request reprint Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors
    Krupa J Patel
    Authors Affiliations Department of Medical Biophysics and Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 19:6766-76. 2013
    ..Here we investigate the effects of pantoprazole, a proton pump inhibitor, on doxorubicin uptake, and doxorubicin distribution and activity using in vitro and murine models...
  53. doi request reprint Company stock prices before and after public announcements related to oncology drugs
    Jeffrey M Rothenstein
    Department of Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada
    J Natl Cancer Inst 103:1507-12. 2011
    ..We examined the stock prices of companies before and after public announcements regarding experimental anticancer drugs owned by the companies...
  54. ncbi request reprint "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer
    Aisha Lofters
    Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
    J Urol 168:2516-20. 2002
    ..High or increasing prostatic specific antigen (PSA) levels may be a source of anxiety in patients with metastatic prostate cancer...
  55. ncbi request reprint The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
    Andrew J Primeau
    Division of Applied Molecular Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:8782-8. 2005
    ..Here, we study the distribution of doxorubicin in relation to blood vessels and regions of hypoxia in solid tumors of mice...
  56. ncbi request reprint Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings
    Philippe L Bedard
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:3482-7. 2007
    ..To investigate the prevalence of underpowered randomized controlled trials (RCTs) presented at American Society of Clinical Oncology (ASCO) annual meetings...
  57. ncbi request reprint Drug resistance and the solid tumor microenvironment
    Olivier Tredan
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Natl Cancer Inst 99:1441-54. 2007
    ....
  58. doi request reprint A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab
    Sophie Kim
    Department of Pharmacy, Princess Margaret Hospital, Toronto, ON, Canada
    J Oncol Pharm Pract 18:293-5. 2012
    ..Both dexamethasone and the total lymphocyte nadir predisposed this patient to PJP...
  59. ncbi request reprint Cognitive impairment associated with chemotherapy for cancer: report of a workshop
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 22:2233-9. 2004
    ....
  60. ncbi request reprint Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study
    Mala Bahl
    The Samuel Lunenfeld Research Institute and Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 94:135-44. 2005
    ..Here, we examine whether serum levels of total cholesterol (TC) and triglycerides (TG) influence breast cancer outcome...
  61. ncbi request reprint Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells
    Philip Wong
    Department of Medical Biophysics and Medical Oncology, Princess Margaret Hospital Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:3553-7. 2005
    ..Although these results add to evidence that manipulation of intracellular pH within the acidic environment of solid tumors can influence the effects of chemotherapy, they are too small and inconsistent to warrant clinical evaluation...
  62. ncbi request reprint Repopulation of cancer cells during therapy: an important cause of treatment failure
    John J Kim
    Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Nat Rev Cancer 5:516-25. 2005
    ..Strategies developed to overcome repopulation have improved clinical outcomes, and now new strategies to inhibit repopulation are emerging in parallel with advances in the understanding of underlying biological mechanisms...
  63. ncbi request reprint Tumor physiology and resistance to chemotherapy: repopulation and drug penetration
    Alison J Davis
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer Treat Res 112:1-26. 2002
  64. doi request reprint Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 30:587-92. 2012
    ..This prospective study investigated receptor status of primary tumors and metastases in the same patient and assessed the impact of discordance on patient management and survival...
  65. ncbi request reprint Intra-individual variability in women with breast cancer
    Lori J Bernstein
    1 Department of Psychosocial Oncology and Palliative Care, Princess Margaret Cancer Centre, Ontario, Canada
    J Int Neuropsychol Soc 20:380-90. 2014
    ..Interpretation of IIV differences requires further investigation. Our results suggest that future studies would benefit from designs that allow analysis of IIV measures in studies assessing cognition in cancer survivors...
  66. ncbi request reprint Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen
    Neil Isaac
    Department of Radiation Oncology, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Ontario, Canada
    Cancer 95:696-703. 2002
    ..The current study was conducted to assess the toxicity of concurrent adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy (RT) for early breast carcinoma...
  67. ncbi request reprint Doctor's dilemma: incorporating tumor markers into clinical decision-making
    Christina M Canil
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, University Health Network, Toronto, Ontario, Canada
    Semin Oncol 29:286-93. 2002
    ....
  68. doi request reprint Cytokines and their relationship to the symptoms and outcome of cancer
    Bostjan Seruga
    Division of Medical Oncology, Princess Margaret Hospital, St Michael s Hospital, University of Toronto, Toronto, Canada
    Nat Rev Cancer 8:887-99. 2008
    ..However, physical activity might modify cytokine levels and decrease fatigue in patients with cancer, and might also improve their prognosis...
  69. pmc Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer
    Ignacio Duran
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    J Gen Intern Med 21:C6-8. 2006
    ..We discuss the pathogenesis, differential diagnosis, and association of DIC with prostate cancer along with the management of this condition...
  70. doi request reprint Broadening horizons in medical management of prostate cancer
    Saroj Niraula
    Division of Hematology and Medical Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Acta Oncol 50:141-7. 2011
    ....
  71. ncbi request reprint Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design
    Alan Tinmouth
    Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Transfusion 44:1711-9. 2004
    ..A randomized controlled trial was undertaken to examine the effectiveness of low-dose PLT transfusions and to determine the need for further studies...